Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH
NCT ID: NCT05860699
Last Updated: 2025-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
210 participants
INTERVENTIONAL
2024-04-08
2026-05-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal
NCT04205682
Effects of Cannabidiol in Alcohol Use Disorder
NCT03252756
Alcohol Use Disorder and Cannabidiol
NCT05613608
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
NCT07148843
Cannabidiol for Reducing Drinking in Alcohol Use Disorder
NCT05159830
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary Endpoint:
Percentage of patients in each group with documented continuous abstinence at month 1 after discharge, week 6 of the study.
Continuous abstinence will be defined by patient's self-report of alcohol abstinence using standardized TLFB (time line follow back) scales TLFB at screening visit and daily from Day 0 to Day 10 and 4 (1 per week) after discharge up to week 6 of the study) Furthermore, this self-declaration will be confirmed by clinical examination at each study visits assessing acute alcohol intoxication signs and 6 ethyl glucuronide (Et-OH) urinary assessments performed at each study visit (2 during the inpatient stay and 4 (1 per week) after discharge up to week 6 of the study).
Secondary objectives :
* To assess the safety of 11 days of up to 900 mg of cannabidiol as an add-on to usual care in the specific population of patients with severe alcohol use disorder during inpatient alcohol cessation
* In case of relapse, reducing alcohol use after discharge up to week 6 of the study
* To reduce alcohol withdrawal symptoms during inpatient alcohol cessation
* To reduce anxiety symptoms during inpatient alcohol cessation
* In a sub-group of patients: describe CBD plasmatic rate and test if it is correlated with side-effects and/or efficacy
* In the sub-group of patients with co-occuring cannabis use, reducing cannabis use after discharge up to week 6 of the study
Secondary endpoints :
* symptoms check list (PRISE-M) of possible side effects every day from day 1 to 10, and then at each outpatient study visit (4 (1 per week) after discharge up to week 6 of the study). Thus any side effect related to treatment exposure as well as treatment cessation (such as anxiety rebound or withdrawal symptoms related to CBD or increase in cannabis use) could be documented
* in case of relapse: drinking days and drinks per day (self-declared using standardized TLFB time line follow back scale over the past week) at the screening visit and daily from Day 0 to Day 10 and 4 (1 per week) after discharge up to week 6 of the study)
* alcohol withdrawal scales and craving scales (CIWA-R, LIKERT craving scale and an adapt version of the OCDS) at the screening visit and every day from day 0 to 10 then at each study visit: 4 (1 per week) after discharge up to week 6 of the study
* state anxiety scale (STAI-6 the short form of the Spielberger inventory, composed of 6 Likert scales) at the screening visit and every day from day 0 to 10 then at each study visit: 4 (1 per week) after discharge up to week 6 of the study
* Pittsburgh Sleep Quality Index (PSQI) at the screening visit and the last visit. A modified daily version every day from day 0 to 10 then at each study visit a modified weekly version: 4 (1 per week) after discharge up to week 6 of the study
* in the subgroup of patients recruited in Fernand Widal hospital, plasmatic level of CBD will be determined twice: at D5 and D10 of the study by Dr Laurence Labat, head of the toxicology department of Lariboisière hospital. Analysis of cannabinoids in human biological specimens of plasma will rely on an extraction process and a chromatographic separation in LCMSHR (Liquid chromatography coupled to high resolution mass spectrometry) for quantification of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), 11-hydroxy Δ9-tetrahydrocannabinol (11-OH THC) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) using deuterated molecules as internal standard. The method was validated in the two biological matrix according to guidelines set forth by COFRAC (Comité d'accréditation Français)
* self-declared current use of all other substances including tobacco products and nicotine replacement therapies, cannabis, and other substances using standardized TLFB (time line follow back) scales ) at the screening visit and every day from day 0 to 10 then at each study visit: 4 (1 per week) after discharge up to week 6 of the study
* in the subgroup of patients who declare themselves as current cannabis users at entry, urinary quantitative determination of cannabinoids by an extraction process and a chromatographic separation in LCMSHR (Liquid chromatography coupled to high resolution mass spectrometry) for quantification of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), 11-hydroxy Δ9-tetrahydrocannabinol (11-OH THC) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) using deuterated molecules as internal standard. The method was validated in the two biological matrix according to guidelines set forth by COFRAC (Comité d'accréditation Français). This analyse will be centralized in the toxicology laboratory of Lariboisière hospital (Pr Laurence Labat). This analyse will be performed 6 times: 2 during the inpatient stay (D5 and D10) and 4 (1 per week) after discharge up to week 6 of the study.
DESIGN
Double Blind Randomized clinical trial with 3 arms :
Patients will undergo one or several outpatient screening visits between D-30 and D-1 of inpatient entry.
During this visit, the study design will be fully explained, inclusion and exclusion criteria checked. Patients will be included during this last visit. Three groups of 70 patients each will be randomized 1:1:1 at entry of a scheduled, usually lasting between 11 and 17 days, alcohol inpatient cessation (D0).
They will all receive oxazepam plus an intervention:
* add-on placebo for 11 days during their inpatient stay
* add-on cannabidiol 450 mg per day for 11 days during their inpatient stay
* add-on cannabidiol 900 mg per day for 11 days during their inpatient stay. All groups will undergo the same prospective follow up after discharge with one visit per week to determine if alcohol abstinence is maintained, up to 1-month post-discharge (week 6 of the study).
In case of a relapse, the amount of alcohol used will be recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
add-on placebo (Echo Pharmaceutical, BV) for 11 days during their inpatient stay
Placebo
Placebo made by the same manufacturer to look like the active pills
Half-dose CBD
add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 11 days during their inpatient stay
Half dose CBD
add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 11 days during their inpatient stay
Full dose CBD
add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 11 days during their inpatient stay
Full dose CBD
add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 11 days during their inpatient stay
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo made by the same manufacturer to look like the active pills
Half dose CBD
add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 11 days during their inpatient stay
Full dose CBD
add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 11 days during their inpatient stay
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-75 years old
* Meeting DSM 5 criteria for severe AUD
* Willing to participate
* Signing a written informed consent
* Patients with current social insurance
* For childbearing age, sexually active females: efficacious contraceptive method during treatment and up to seven days after treatment administration
Exclusion Criteria
* Patients not willing to attend post-discharge visits whatever the reason
* Any unstable medical condition at entry, such as delirium, acute hepatic failure, hypokalaemia, liver cirrhosis whatever the stage, acute or chronic severe renal failure or any acute psychiatric condition
* Liver enzymes (ALT and/or AST) above 3 times the upper limit of normal and/or bilirubin above 2 times the upper limit of normal
* Current medication or need for medication with treatments metabolized by CYP 2C19 or CYP3A4 or UGT enzymes and having strong inhibitor/inducer properties (see list above), and/or current medication or need for medications containing valproate and derivates
* Any medical history of epileptic seizure
* Patients with current or past history of cardiac arrhythmias, myocardial infarction and stroke
* Any history of suicidal attempt in the past 5 years or a score ≥1 to the Suicidal Ideation Attributes Scale (SIDAS)
* To facilitate efficacy data interpretation, patients currently receiving or wanting to receive another approved pharmacological treatment aimed at alcohol abstinence maintenance (acamprosate, baclofene, disulfiram, nalmefene, naltrexone).
* Other major current DSM 5 severe substance use disorder (like opiates, cocaine, amphetamines, ...) except for tobacco, cannabis smoking and benzodiazepines use disorders
* Pregnancy and breast feeding
* Known hypersensitivity to the active substance or to any of the excipients (including PEG)
* Patients under guardianship
* Patients in exclusion periods of other trials
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Florence Vorspan
Role: PRINCIPAL_INVESTIGATOR
Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, AP-HP Inserm UMR-S 1144 Université de Paris FHU NOR-SUD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Hôtel-Dieu
Paris, Paris, France
Hôpital Cochin
Paris, Paris, France
Hôpital Saint Anne
Paris, Paris, France
Hôpital Bichat
Paris, Paris, France
Hôpital René Muret
Sevran, Sevran, France
Hôpital la Colombière
Montpellier, , France
Hôpital Avicenne
Bobigny, France, France
Hôpital Fernand Widal
Paris, France, France
Hôpital Albert Chenevier
Créteil, Albert Chenevier, France
Hôpital Antoine Béclère
Clamart, Clamart, France
CHU Gabriel Montpied
Clermont-Ferrand, Clermont Ferrand, France
Hôpital Louis Mourier
Colombes, Colombes, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP180619
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.